methamphetamine has been researched along with Parkinsonian Disorders in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (60.87) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, K; Inoue, R; Kawai, K; Nishime, C; Nishinaka, E; Tsutsumi, H; Urano, K | 1 |
| Gupta, SP; Mishra, SK; Singh, MP; Singhal, NK; Tiwari, MN; Yadav, S | 1 |
| Dagda, RK; Das Banerjee, T; Janda, E | 1 |
| Hisahara, S; Honmou, O; Iwahara, N; Kawamata, J; Matsumura, A; Matsushita, T; Sasaki, M; Shimohama, S; Suzuki, S | 1 |
| Grill, WM; McConnell, GC; So, RQ | 2 |
| Asanuma, M; Miyazaki, I | 1 |
| Kishimoto, K; Kitamura, Y; Minamino, H; Shibaike, T; Shimohama, S; Takata, K; Takeuchi, H; Taniguchi, T; Tsushima, J; Yanagida, T; Yasui, H | 1 |
| Biagioni, F; Fornai, F; Fulceri, F; Murri, L; Paparelli, A; Ruggieri, S | 1 |
| Rusyniak, DE | 1 |
| August, AT; Grill, WM; McConnell, GC; So, RQ | 1 |
| Asakawa, T; Ito-Yamashita, T; Namba, H; Sugiyama, K; Sun, W | 1 |
| Alessandrí, MG; Fornai, F; Geppert, M; Jahn, R; Schlüter, OM; Südhof, TC; Takamori, S | 1 |
| Aiken, SS; Ang, L; Fitzmaurice, P; Kalasinsky, KS; Kish, SJ; Moszczynska, A; Peretti, FJ; Schmunk, GA; Wickham, DJ | 1 |
| Bannai, M; Kondoh, T; Nishino, H; Torii, K | 1 |
| Hayashi, K; Inden, M; Inoue, K; Kim, DH; Kitamura, Y; Nishimura, K; Qi, M; Shimohama, S; Sumi, S; Takata, K; Taniguchi, T; Tsuchiya, D; Yanagisawa, D; Yoshimoto, K | 1 |
| Ando, K; Higuchi, M; Inaji, M; Maeda, J; Nagai, Y; Nariai, T; Obayashi, S; Ohno, K; Okano, H; Okauchi, T; Suhara, T; Yoshizaki, T | 1 |
| Dluzen, DE; Liu, B | 1 |
| Bandettini Di Poggio, A; De Blasi, A; Fornai, F; Lazzeri, G; Nicoletti, F; Paparelli, A; Ruggieri, S; Soldani, P | 1 |
| Bell, KP; Choi, PK; Clarkson, ED; Esplen, JE; Freed, CR; Heidenreich, KA; Zawada, WM | 1 |
| Cadet, JL | 1 |
| Anderson, LI; Dluzen, DE; Kucera, J; McDermott, JL; Walro, JM | 1 |
| Hashiguchi, H; Ishida, Y; Mitsuyama, Y; Nishimori, T; Takeda, R; Todaka, K | 1 |
6 review(s) available for methamphetamine and Parkinsonian Disorders
| Article | Year |
|---|---|
Does restraining nitric oxide biosynthesis rescue from toxins-induced parkinsonism and sporadic Parkinson's disease?
Topics: Animals; Humans; Methamphetamine; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Oxidopamine; Parkinson Disease, Secondary; Parkinsonian Disorders; Reactive Nitrogen Species; Rotenone | 2014 |
How Parkinsonian toxins dysregulate the autophagy machinery.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Autophagy; Humans; Methamphetamine; Mitophagy; MPTP Poisoning; Neurotoxins; Oxidopamine; Paraquat; Parkinsonian Disorders; Rotenone | 2013 |
Approaches to prevent dopamine quinone-induced neurotoxicity.
Topics: Animals; Dopamine; Humans; Methamphetamine; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders | 2009 |
Intermittent Dopaminergic stimulation causes behavioral sensitization in the addicted brain and parkinsonism.
Topics: Amphetamine-Related Disorders; Animals; Brain; Dopamine; Humans; Levodopa; Methamphetamine; Parkinsonian Disorders; Receptors, Dopamine D1; Signal Transduction | 2009 |
Neurologic manifestations of chronic methamphetamine abuse.
Topics: Amphetamine-Related Disorders; Central Nervous System Stimulants; Dyskinesia, Drug-Induced; Humans; Methamphetamine; Paresthesia; Parkinsonian Disorders | 2011 |
Molecular neurotoxicological models of Parkinsonism: focus on genetic manipulation of mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Humans; Methamphetamine; Mice; Mice, Knockout; Mice, Transgenic; Neurotoxins; Oxidopamine; Parkinsonian Disorders | 2001 |
17 other study(ies) available for methamphetamine and Parkinsonian Disorders
| Article | Year |
|---|---|
Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine.
Topics: Animals; Apomorphine; Area Under Curve; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopaminergic Neurons; Dose-Response Relationship, Drug; Immunohistochemistry; Levodopa; Male; Methamphetamine; Motor Activity; Oxidopamine; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2017 |
Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats.
Topics: Animals; Dopaminergic Neurons; Female; Humans; Mesenchymal Stem Cell Transplantation; Methamphetamine; Nerve Degeneration; Neuroglia; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra; Tyrosine 3-Monooxygenase | 2015 |
Failure to suppress low-frequency neuronal oscillatory activity underlies the reduced effectiveness of random patterns of deep brain stimulation.
Topics: Action Potentials; Animals; Central Nervous System Stimulants; Deep Brain Stimulation; Dopamine D2 Receptor Antagonists; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Haloperidol; Implantable Neurostimulators; Methamphetamine; Microelectrodes; Neural Inhibition; Neurons; Oxidopamine; Parkinsonian Disorders; Pars Reticulata; Rats, Long-Evans; Subthalamic Nucleus | 2016 |
Frequency-dependent, transient effects of subthalamic nucleus deep brain stimulation on methamphetamine-induced circling and neuronal activity in the hemiparkinsonian rat.
Topics: Analysis of Variance; Animals; Central Nervous System Stimulants; Deep Brain Stimulation; Disease Models, Animal; Dose-Response Relationship, Radiation; Linear Models; Male; Methamphetamine; Neurons; Parkinsonian Disorders; Rats; Rats, Long-Evans; Subthalamic Nucleus; Time Factors | 2017 |
Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Electron Spin Resonance Spectroscopy; Functional Laterality; Galantamine; Gene Expression Regulation; Male; Mecamylamine; Methamphetamine; Motor Activity; Neuroprotective Agents; Nicotine; Nicotinic Antagonists; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Nicotinic; RNA, Messenger; Rotarod Performance Test; Tyrosine 3-Monooxygenase | 2008 |
Characterizing effects of subthalamic nucleus deep brain stimulation on methamphetamine-induced circling behavior in hemi-Parkinsonian rats.
Topics: Animals; Behavior, Animal; Deep Brain Stimulation; Mental Disorders; Methamphetamine; Parkinsonian Disorders; Rats; Rats, Long-Evans; Subthalamic Nucleus; Treatment Outcome | 2012 |
Behavioral performance at early (4 weeks) and later (6 months) stages in rats with unilateral medial forebrain bundle and striatal 6-hydroxydopamine lesions.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Bromocriptine; Corpus Striatum; Injections; Male; Medial Forebrain Bundle; Methamphetamine; Motor Skills; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereotyped Behavior | 2013 |
Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Synuclein; Animals; Antibodies; Blastomeres; Blotting, Southern; Corpus Striatum; Disease Models, Animal; DNA Primers; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Glutamic Acid; Hippocampus; Homovanillic Acid; Humans; Immunoblotting; Immunohistochemistry; Methamphetamine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; MPTP Poisoning; Nerve Tissue Proteins; Neurons; Parkinsonian Disorders; Piperazines; Rats; Reserpine; Serotonin; Stem Cells; Subcellular Fractions; Substantia Nigra; Synucleins; Tyrosine 3-Monooxygenase | 2003 |
Why is parkinsonism not a feature of human methamphetamine users?
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Brain; Cause of Death; Central Nervous System Stimulants; Corpus Striatum; Dopamine; Female; Humans; Male; Methamphetamine; Parkinsonian Disorders; Putamen | 2004 |
6-Hydroxydopamine-induced lesions in a rat model of hemi-Parkinson's disease monitored by magnetic resonance imaging.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Immunohistochemistry; Magnetic Resonance Imaging; Male; Methamphetamine; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Predictive Value of Tests; Rats; Rats, Wistar; Rotation; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Transplantation of mouse embryonic stem cell-derived neurons into the striatum, subthalamic nucleus and substantia nigra, and behavioral recovery in hemiparkinsonian rats.
Topics: Animals; Basal Ganglia; Behavior, Animal; Brain Tissue Transplantation; Cell Count; Corpus Striatum; Denervation; Disease Models, Animal; Graft Survival; Growth Cones; Hyperkinesis; Male; Methamphetamine; Mice; Neurons; Oxidopamine; Parkinsonian Disorders; Pluripotent Stem Cells; Rats; Rats, Wistar; Recovery of Function; Stem Cell Transplantation; Substantia Nigra; Subthalamic Nucleus | 2005 |
Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Autoradiography; Behavior, Animal; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Functional Laterality; Male; Methamphetamine; Movement; Neostriatum; Neurons; Oxidopamine; Parkinsonian Disorders; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2005 |
Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Estrogens; Female; Male; Methamphetamine; Mice; Nerve Degeneration; Neural Pathways; Neuroprotective Agents; Neurotoxins; Orchiectomy; Ovariectomy; Parkinsonian Disorders; Substantia Nigra | 2006 |
Convergent roles of alpha-synuclein, DA metabolism, and the ubiquitin-proteasome system in nigrostriatal toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Methamphetamine; Neurotoxins; Parkinsonian Disorders; PC12 Cells; Proteasome Endopeptidase Complex; Rats; Substantia Nigra; Ubiquitin | 2006 |
IGF-I and bFGF improve dopamine neuron survival and behavioral outcome in parkinsonian rats receiving cultured human fetal tissue strands.
Topics: Abortion, Induced; Animals; Apomorphine; Brain; Brain Tissue Transplantation; Cell Survival; Cells, Cultured; Disease Models, Animal; Dopamine; Female; Fetal Tissue Transplantation; Fibroblast Growth Factor 2; Homovanillic Acid; Humans; Insulin-Like Growth Factor I; Male; Methamphetamine; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Rats, Sprague-Dawley; Rotation; Transplantation, Heterologous; Tyrosine 3-Monooxygenase | 2001 |
Striatal dopamine output is compromised within +/- BDNF mice.
Topics: Animals; Brain-Derived Neurotrophic Factor; Dopamine; Drug Interactions; Extracellular Space; Female; Genotype; Male; Methamphetamine; Mice; Mice, Inbred BALB C; Mice, Knockout; Neostriatum; Neural Pathways; Neurons; Parkinsonian Disorders; Perfusion; Potassium; Substantia Nigra | 2002 |
Morphological changes in immunopositive cells of ionotropic glutamate receptor subunits during the development of transplanted fetal ventral mesencephalic neurons.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Differentiation; Disease Models, Animal; Female; Fetal Tissue Transplantation; Graft Survival; Immunohistochemistry; Mesencephalon; Methamphetamine; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Tyrosine 3-Monooxygenase | 2002 |